The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy. - Fujita, Kazutoshi; Matsushita, Yuto; Toyoda, Shingo; Kojima, Takahiro; Yamashita, Shimpei; Taniguchi, Hisanori; Monji, Keisuke; Ishiyama, Ryo; Tatarano, Shuichi; Masui, Kimihiko; Nakamura, Eijiro; Kaneko, Tomoyuki; et al. (World Journal of Urology, 2024)